Swiss biotech firm, Page Therapeutics, appoints Dr. Meret Gaugler as independent board member to guide transition to clinical trials.

Page Therapeutics, a Swiss biotech firm focused on metastatic cancer, has appointed Dr. Meret Gaugler as an independent board member. With over 14 years of experience in life sciences investment, Gaugler will guide the company's transition to clinical trials. Page Therapeutics aims to develop therapies that target circulating tumor cells and prevent metastasis formation.

October 25, 2024
3 Articles

Further Reading